Sapporo Medical Journal

Abstract : Based on the data from "World Kidney Day", there are at least 1 out of 10 people around the world with a certain level of morbidity that leads to Chronic Kidney Disease (CKD). Many studies have shown that oxidative stress contributes to the progression of CKD. This study aims to compare malondialdehyde (MDA) and 8-dihydro-2-deoxyguanosine (8-OHdG) as oxidative stress markers in CKD patients who were treated with angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and who were not treated with both therapies. In this study, fifty-four hospitalized CKD patients were recruited randomly from three different hospitals in Surabaya, Indonesia. This study’s subjects were grouped based on their consumption of ACEi/ARB. Oxidative stress markers, MDA and 8-OHdG, were calculated using the Mann-Whitney test with a p-value<0.05. Urinary MDA in the patients receiving ACEi/ARB was lower than those who did not receive (3.75 (2.24-9.92) vs 5.16 (2.61-19.41); p=0.002). Urinary 8-OHdG in the patients receiving ACEi/ARB was lower than those who did not receive any (4.11 (0.36-20.26) vs 6.61 (1.76-31.35); p=0.028). There were positive correlations between urinary MDA and urinary creatinine (R=0,547; p=0,000) and between urinary 8-OHdG and urinary creatinine (R=0,630; p=0,000). These results implicate that ACEi/ARB administration in CKD patients is beneficial for reducing urinary oxidative stress markers.